Real-World Evidence 2.0: From Post-Market Validation to Strategic Design
In 2025, Real-World Evidence (RWE) is no longer an afterthought in regulatory filings. It’s a design principle. We recently worked with a biotech firm developing an oncology therapy struggling with limited trial enrollment and payer skepticism. Instead of waiting until post-launch to demonstrate real-world value, they embedded RWE from day one. By integrating claims and […]
